| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
30,111,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.000001 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sophiris Bio is a biopharmaceutical company focused on developing products for the treatment of urological diseases. Co. is developing topsalysin (PRX302) as a treatment for clinically primary localized prostate cancer and as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia, commonly referred to as an enlarged prostate. Topsalysin, a recombinant protein, is delivered via ultrasound-guided injection directly into the prostate. This protein is selectively activated by enzymatically active prostate specific antigen, which is found around prostate tumor cells, resulting in localized cell death and tissue disruption without damage to neighboring tissue and nerves.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Woods Randall E |
President & Chief Exec Officer |
• • – |
2018-09-19 |
4 |
B |
$2.63 |
$26,339 |
D/D |
10,000 |
10,000 |
2.81 |
- |
|
| Heppell James L |
Director |
– • – |
2016-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
38 |
11,188 |
|
- |
|
| Ekman Lars |
Director |
– • – |
2014-12-18 |
4 |
S |
$0.47 |
$4,542 |
I/I |
(9,663) |
520 |
|
- |
|
| Mva Investors, Llc |
10% Owner |
– – • |
2014-12-15 |
4 |
S |
$0.61 |
$537,702 |
D/D |
(881,479) |
161,447 |
|
- |
|
| Woods Randall E |
President & Chief Exec Officer |
• • – |
2014-11-14 |
4 |
B |
$2.43 |
$7,290 |
I/I |
3,000 |
17,500 |
2.58 |
- |
|
| Proehl Gerald T |
Director |
– • – |
2014-09-19 |
4 |
B |
$3.16 |
$31,599 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Woods Randall E |
President & Chief Exec Officer |
• • – |
2014-07-10 |
4 |
B |
$2.65 |
$2,650 |
I/I |
1,000 |
14,500 |
2.58 |
- |
|
| Woods Randall E |
President & Chief Exec Officer |
• • – |
2014-07-09 |
4 |
B |
$2.66 |
$2,663 |
I/I |
1,000 |
13,500 |
2.58 |
- |
|
| Heppell James L |
Director |
– • – |
2014-06-06 |
4 |
S |
$2.59 |
$49,808 |
I/I |
(19,231) |
0 |
|
- |
|
9 Records found
|
1
|
Page 1 of 1 |
|
|
